Getting your Trinity Audio player ready...

Today’s market surge has brought several key companies into the spotlight, capturing significant investor attention. This feature provides a detailed analysis of five standout stocks, offering insights that could be crucial for investors in the near future.

Actelis Networks Inc. (NASDAQ: ASNS) continues its upward trend, soaring 62% in early trading on Tuesday. The stock has surged nearly 265% over the past month. Today, the company announced a partnership with Carahsoft Technology Corp., a leading government IT solutions provider. Under this agreement, Carahsoft will serve as Actelis’ Public Sector distributor, delivering Actelis’ hybrid-fiber connectivity solutions to federal, state, and local agencies, as well as educational organizations in the U.S. and Canada through Carahsoft’s reseller partners and contracts with NASA SEWP V and OMNIA Partners.

Peraso Inc. (NASDAQ: PRSO), a leader in mmWave technology, recently saw Director Ian McWalter purchase 100,000 shares, increasing his holdings to 101,246 shares. On June 12, 2024, Ladenburg Thalmann initiated coverage of Peraso with a Buy rating and a price target of $3.75, citing the company’s strong position in the growing mmWave market. Research indicates that the mmWave market, valued at $3.75 billion in 2023, is expected to grow significantly, driven by high-speed IoT and bandwidth-intensive applications. Peraso’s stock, currently showing bullish indicators, has seen a substantial increase in trading volume, making it a stock to watch closely.

Reliance Global Group, Inc. (NASDAQ: RELI) emerged as one of Tuesday’s top gainers, skyrocketing 291% to $0.87. This surge follows a positive investor response to the company’s update on the pending acquisition of Spetner Associates. Ezra Beyman, Chairman and CEO of Reliance Global Group, announced that the impact of the Spetner Associates acquisition is exceeding expectations. Spetner’s BenManage voluntary benefit insurance segment has significantly expanded, now covering 85,000 employees, up from 45,000 at the time of the acquisition announcement. Despite the lengthy transaction and due diligence process, Beyman highlighted the continued growth of the underlying business. This acquisition is expected to be the largest in the company’s history and a pivotal moment, projected to double annual revenues to an estimated $28 million.

Catheter Precision Inc. (NYSE American: VTAK), a leading U.S.-based medical device company specializing in electrophysiology, announced a new purchase order for its latest product, LockeT, on June 17, 2024. In preparation for the nationwide launch of LockeT, the company has expanded its U.S. sales and clinical team. The stock has seen a significant surge in trading volume, outperforming key moving averages, with a recent five-day average of 418,000 shares compared to a 60-day average of 66,242 shares, indicating potential breakout opportunities. Additionally, Eisenhower Medical Center in California placed a new purchase order following a successful evaluation, marking the third such order from California hospitals since early May. The company’s commitment to innovative solutions and collaboration with physicians is evident in its key products, VIVO(TM) and LockeT. Read Entire Update Now!

Aethlon Medical, Inc. (NASDAQ: AEMD) continues its strong uptrend, climbing another 13% and extending its monthly gains to 68%. Today, the company announced that on June 13, 2024, the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network (CALHN) granted full ethics approval for Aethlon’s clinical trial of the Hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatments, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab). This approval, valid for three years until June 13, 2027, allows the trial to be conducted by Prof. Michael Brown and his team at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Adelaide, Australia.